Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Clinical trial NCT05626322 · TERMINATED
Trial details
- NCT number
- NCT05626322
- Sponsor
- Pfizer
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-04
- Primary completion
- 2024-08-12
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.